Wise Medical's Aesthetic Devices Gain Regulatory Approval: Committed to Long-Term Investment and Confident in Global Expansion Strategy

‍

Smart Medical Device Network NewsRecently,According to VISHEE, it is preliminarily expected that from the fourth quarter of this year to the whole of next year, the favorable policies for equipment updates in the medical field will gradually boost demand for medical device businesses. The incremental performance brought by these policies is expected to be gradually reflected from the fourth quarter of 2024 to the whole of 2025.

According to VISHEE's management, the company has built six major technology platforms: magnetic stimulation, electrical stimulation, electrophysiology, robotics, laser, and radiofrequency, forming a professional and expandable underlying technology platform.

Among them, in the field of magnetic stimulation, the company's second-generation transcranial magnetic stimulator (rehabilitation dedicated) provides internationally advanced non-invasive neuromodulation treatment methods for neurorehabilitation, meeting personalized and precise rehabilitation needs.

In the field of electrophysiology, the company possesses video EEG signal synchronization technology, automatic identification technology for multi-channel EEG caps, as well as various automated analysis and processing algorithms for electrophysiological data based on big data, including automatic recognition of EEG background, automatic determination of sleep-wake cycles, and identification of burst suppression and seizures. The various functions developed around these technologies provide comprehensive support for the application of the company’s neonatal EEG measuring instrument in the field of neonatal brain function monitoring and screening.

Data shows that VISHEE is a technology innovation-driven medical device company, a national high-tech enterprise, a STAR Market listed company, and a national-level specialized, refined, novel "little giant" enterprise. The company provides high-quality products and solutions for rehabilitation medicine, with pelvic floor and postpartum rehabilitation, mental health rehabilitation, neurological rehabilitation, and pediatric rehabilitation as its strengths and features, widely used in various medical institutions in China, including general hospitals, gynecology and obstetrics specialty hospitals, psychiatric specialty hospitals, children's specialty hospitals, and rehabilitation specialty hospitals.Hospitals, etc.

At the same time, VISHEE actively incubates medical aesthetics and urology businesses with energy-based devices as the core product matrix, benchmarks against international competitors, and builds a first-line brand produced in China.

The company has long been committed to applying the most cutting-edge technology to products that improve patients' quality of life, gradually establishing technical platforms in magnetic stimulation, electrical stimulation, electrophysiology, rehabilitation robotics, radiofrequency, and laser. It owns core product brands such as the transcranial magnetic stimulator MagNeuro, pelvic floor magnetic stimulator MagBelle, body contouring magnetic stimulator MagGraver, biofeedback stimulator SA980X, group biofeedback device Freemind, holmium laser treatment device Curestar, intelligent rehabilitation training system Xlocom, and high-frequency electrocautery device RFIntima.

In terms of performance, Nanjing Vishee Medical Technology Co., Ltd. achieved a total operating revenue of 292 million yuan in the first three quarters of 2024, representing a year-on-year decrease of 12.06%; the net profit attributable to shareholders of the listed company was 78.1663 million yuan, marking a year-on-year decrease of 23.13%.

In the first three quarters of this year, VISHEE's multi-pipeline R&D new products, such as the automatic navigation transcranial magnetic stimulation instrument MagNeuro ONE series, extracorporeal shock wave, and picosecond laser, have successfully obtained certification. The product portfolio is becoming increasingly enriched, accelerating the formation of new growth points.

High-frequency electrocautery devices and shaping magnetic products have continued to achieve sales breakthroughs in the maternal and child channels and the light medical aesthetics market, receiving positive market feedback. This provides new momentum for the transformation of pelvic floor business and the expansion of medical aesthetics business.

VISHEE's mental health business has maintained a strong growth momentum despite a high base in the same period. It has developed a mature and systematic solution for physical diagnosis and treatment centers in psychiatry, further consolidating its leading position in the niche market.

In 2024, the neurorehabilitation business successfully transitioned from "single product" to "premium solution." The extracorporeal shock wave product was approved in June 2024, forming a strong synergy with existing electromagnetic products. The company's comprehensive competitiveness in rehabilitation therapy and pain management continues to improve.

It is reported that VISHEE's Nd:YAG frequency-doubled picosecond laser treatment device obtained approval from the National Medical Products Administration (NMPA) at the end of September, receiving the relevant Class III medical device certification. This makes it the first picosecond laser product in China for treating pigmented diseases to be verified through large-scale registration clinical trials at top-tier hospitals.

For hyperpigmentation diseases, such as freckles and age spots, the company's products have undergone clinical trials at top dermatology hospitals in China. The experimental process also adopted a double-blind method, where two types of picosecond devices were used to treat the left and right cheeks of the subjects respectively. Additionally, the treatment results for each subject were confirmed through precise counting by three doctors both before and after the treatment.

The pigment removal rate of the company's product shows no difference compared to imported benchmark products. Additionally, the product demonstrates safe usage, with no severe adverse events reported among all subjects; only mild adverse events occurred, and the incidence rate is comparable to competitors. With the certification of the picosecond device, the company has officially entered the dermatology sector. Subsequent efforts will focus on increasing sales investment and accelerating the launch and promotion of follow-up products.

For medical aesthetics business, according to VISHEE: "In terms of medical aesthetics, especially skin-related services, we have not officially started yet, but there is an opportunity to gain incremental growth in the future. Regarding policies, regardless of their intensity, we are more focused on enhancing our own capabilities and restoring business growth as soon as possible."

It is worth mentioning that VISHEE also emphasized: "The company has started to layout the access to foreign markets since this year, and completed the first stage.The market access for core products in key countries typically takes about 1-2 years, so we will complete the first round of product registrations by the end of next year. From a market perspective, there are certain differences in demand for equipment related to rehabilitation and medical aesthetics between the Chinese market and overseas markets. We also need more time to understand and cultivate foreign markets. However, going global is definitely the right direction, and the company will continue with long-term investments. Overseas sales revenue has already been generated.